Taken together, our data reveal that the Hippo-YAP/TAZ pathway is critical in conferring and sustaining resistance to KRAS inhibitors, and modulation of this pathway holds promise for overcoming resistance to KRAS inhibitors and improving outcomes for patients with KRAS-mutant cancers. This evidence concerns the gene YAP1 and cancer.